Ashley Lora joined an eczema clinical trial for DUPIXENT and paved the way for other Black women to try clinical trials.

The key secondary endpoints (also assessed at 24 weeks) included change from baseline in itch and hives (weekly ... in people with atopic dermatitis and asthma who receive DUPIXENT.

“With this FDA decision, Dupixent is now approved for seven chronic, debilitating atopic conditions driven in part by underlying type 2 inflammation, several of which have been shown to co-morbidly ...

The mechanism of action sets temtokibart apart from established eczema drugs such as Sanofi and Regeneron’s blockbuster immunology med Dupixent ... to severe atopic dermatitis, the most common ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...

The key secondary endpoints (also assessed at 24 weeks) included change from baseline in itch and hives (weekly ... Dupixent has received regulatory approvals in more than 60 countries in one or more ...